Sign In
Buy PTGX
$95.41
+2.18 (+2.34%)
At Close: Jun 03, 2026
Protagonist Therapeutics (NASDAQ:PTGX) CEO Dinesh Ph Patel Sells 24,890 Shares of Stock
05:34am, Wednesday, 28'th Jan 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX - Get Free Report) CEO Dinesh Ph Patel sold 24,890 shares of the stock in a transaction on Monday, January 26th. The stock was sold at an average price of
Protagonist Therapeutics, Inc. (PTGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
05:35pm, Tuesday, 13'th Jan 2026
Protagonist Therapeutics, Inc. (PTGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
07:30am, Wednesday, 07'th Jan 2026
NEWARK, CA / ACCESS Newswire / January 7, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
07:00am, Monday, 05'th Jan 2026
OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug App
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Rating of “Moderate Buy” from Analysts
01:49am, Wednesday, 31'st Dec 2025
Protagonist Therapeutics, Inc. (NASDAQ: PTGX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the fourteen research firms that are currently covering the firm, Mar
Assenagon Asset Management S.A. Decreases Stock Holdings in Protagonist Therapeutics, Inc. $PTGX
03:18am, Monday, 22'nd Dec 2025
Assenagon Asset Management S.A. lowered its position in shares of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) by 28.4% in the third quarter, according to the company in its most recent Form 13F fili
Bosun Asset Management LLC Acquires New Position in Protagonist Therapeutics, Inc. $PTGX
04:32am, Sunday, 07'th Dec 2025
Bosun Asset Management LLC bought a new stake in Protagonist Therapeutics, Inc. (NASDAQ: PTGX) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securi
NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results fro
Protagonist Therapeutics, Inc. $PTGX Shares Bought by Commonwealth of Pennsylvania Public School Empls Retrmt SYS
04:09am, Monday, 24'th Nov 2025
Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) by 11.6% in the undefined quarter, according to the company i
Protagonist Therapeutics, Inc. $PTGX Stock Holdings Trimmed by Aviva PLC
04:00am, Friday, 14'th Nov 2025
Aviva PLC lowered its position in shares of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) by 28.5% during the undefined quarter, according to its most recent disclosure with the Securities and Exchang
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates
06:46pm, Thursday, 06'th Nov 2025
Protagonist Therapeutics (PTGX) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to a loss of $0.54 per share a year ago.
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update
04:05pm, Thursday, 06'th Nov 2025
Following the NDA submission for icotrokinra treatment of adults and adolescents with moderate to severe plaque psoriasis to the U.S. FDA in July, the European Medicines Agency (EMA) application was s
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting
04:05pm, Monday, 03'rd Nov 2025
NEWARK, CALIFORNIA / ACCESS Newswire / November 3, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that clinical data on rusfertide in polycythemia vera, including the
Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy?
11:06am, Thursday, 30'th Oct 2025
Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Price Target at $72.00
01:30am, Monday, 20'th Oct 2025
Shares of Protagonist Therapeutics, Inc. (NASDAQ: PTGX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the twelve brokerages that are presently covering the firm, Ma
